These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Leishmania amazonensis from distinct clinical forms/hosts has polymorphisms in Lipophosphoglycans, displays variations in immunomodulatory properties and, susceptibility to antileishmanial drugs. Rêgo FD; Cardoso CDA; Moreira POL; Nogueira PM; Araújo MS; Borges VM; Laurenti MD; Bartholomeu DC; Reis AB; Monte-Neto RLD; Soares RP Cell Biol Int; 2022 Nov; 46(11):1947-1958. PubMed ID: 35998255 [TBL] [Abstract][Full Text] [Related]
26. Leishmania lipophosphoglycan: how to establish structure-activity relationships for this highly complex and multifunctional glycoconjugate? Forestier CL; Gao Q; Boons GJ Front Cell Infect Microbiol; 2014; 4():193. PubMed ID: 25653924 [TBL] [Abstract][Full Text] [Related]
27. Differential Impact of LPG-and PG-Deficient Leishmania major Mutants on the Immune Response of Human Dendritic Cells. Favila MA; Geraci NS; Jayakumar A; Hickerson S; Mostrom J; Turco SJ; Beverley SM; McDowell MA PLoS Negl Trop Dis; 2015 Dec; 9(12):e0004238. PubMed ID: 26630499 [TBL] [Abstract][Full Text] [Related]
28. In vitro infectivity of species of Leishmania (Viannia) responsible for American cutaneous leishmaniasis. Campos MB; De Castro Gomes CM; de Souza AA; Lainson R; Corbett CE; Silveira FT Parasitol Res; 2008 Sep; 103(4):771-6. PubMed ID: 18528708 [TBL] [Abstract][Full Text] [Related]
29. Morita-Baylis-Hillman adduct shows in vitro activity against Leishmania (Viannia) braziliensis associated with a reduction in IL-6 and IL-10 but independent of nitric oxide. Amorim FM; Rodrigues YK; Barbosa TP; Néris PL; Caldas JP; Sousa SC; Leite JA; Rodrigues-Mascarenhas S; Vasconcellos ML; Oliveira MR Parasitology; 2013 Jan; 140(1):29-38. PubMed ID: 22906971 [TBL] [Abstract][Full Text] [Related]
30. Mast cells are activated by Leishmania mexicana LPG and regulate the disease outcome depending on the genetic background of the host. Villaseñor-Cardoso MI; Salaiza N; Delgado J; Gutiérrez-Kobeh L; Pérez-Torres A; Becker I Parasite Immunol; 2008 Aug; 30(8):425-34. PubMed ID: 18507782 [TBL] [Abstract][Full Text] [Related]
31. Exacerbation of Leishmania (Viannia) shawi infection in BALB/c mice after immunization with soluble antigen from amastigote forms. Passero LF; Da Costa Bordon ML; De Carvalho AK; Martins LM; Corbett CE; Laurenti MD APMIS; 2010 Dec; 118(12):973-81. PubMed ID: 21091779 [TBL] [Abstract][Full Text] [Related]
32. Regulation of the expression of nitric oxide synthase and leishmanicidal activity by glycoconjugates of Leishmania lipophosphoglycan in murine macrophages. Proudfoot L; Nikolaev AV; Feng GJ; Wei WQ; Ferguson MA; Brimacombe JS; Liew FY Proc Natl Acad Sci U S A; 1996 Oct; 93(20):10984-9. PubMed ID: 8855295 [TBL] [Abstract][Full Text] [Related]
33. Histopathology, humoral and cellular immune response in the murine model of Leishmania (Viannia) shawi. Passero LF; Marques C; Vale-Gato I; Corbett CE; Laurenti MD; Santos-Gomes G Parasitol Int; 2010 Jun; 59(2):159-65. PubMed ID: 20060062 [TBL] [Abstract][Full Text] [Related]
34. Leishmania braziliensis: a novel mechanism in the lipophosphoglycan regulation during metacyclogenesis. Soares RP; Cardoso TL; Barron T; Araújo MS; Pimenta PF; Turco SJ Int J Parasitol; 2005 Mar; 35(3):245-53. PubMed ID: 15722076 [TBL] [Abstract][Full Text] [Related]
35. New insights to structure and immunological features of Leishmania lipophosphoglycan3. Hosseini M; Haji-Fatahaliha M; Miahipour A; Yousefi M Biomed Pharmacother; 2017 Nov; 95():1369-1374. PubMed ID: 28946184 [TBL] [Abstract][Full Text] [Related]
36. Leishmania mexicana: participation of NF-kappaB in the differential production of IL-12 in dendritic cells and monocytes induced by lipophosphoglycan (LPG). Argueta-Donohué J; Carrillo N; Valdés-Reyes L; Zentella A; Aguirre-García M; Becker I; Gutiérrez-Kobeh L Exp Parasitol; 2008 Sep; 120(1):1-9. PubMed ID: 18508052 [TBL] [Abstract][Full Text] [Related]
37. Lipophosphoglycan From Dermotropic New World Silveira MB; Gomes RS; Shio MT; Rugani JN; Paranaiba LF; Soares RP; Ribeiro-Dias F Front Cell Infect Microbiol; 2022; 12():805720. PubMed ID: 35402314 [TBL] [Abstract][Full Text] [Related]
38. Impairment of Leishmania mexicana phagocytosis in peritoneal macrophages induced by Amaranthus leucocarpus lectin. Gorocica P; Hernández P; Perez A; Chávez R; Baez R; Zenteno E; Lascurain R Immunol Invest; 2000 Nov; 29(4):373-82. PubMed ID: 11130780 [TBL] [Abstract][Full Text] [Related]
39. Transmission blocking vaccine studies in leishmaniasis: II. Effect of immunisation using Leishmania major derived 63 kilodalton glycoprotein, lipophosphoglycan and whole parasite antigens on the course of L. major infection in BALB/c mice. Tonui WK; Mbati PA; Anjili CO; Orago AS; Turco SJ; Githure JI; Koech DK East Afr Med J; 2001 Feb; 78(2):90-2. PubMed ID: 11682953 [TBL] [Abstract][Full Text] [Related]
40. Glycoconjugates isolated from Trypanosoma cruzi but not from Leishmania species membranes trigger nitric oxide synthesis as well as microbicidal activity in IFN-gamma-primed macrophages. Camargo MM; Andrade AC; Almeida IC; Travassos LR; Gazzinelli RT J Immunol; 1997 Dec; 159(12):6131-9. PubMed ID: 9550414 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]